		·	
	Application No.	Applicant(s)	
	09/995,277	BAELL ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Phyllis G. Spivack	1614	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) of NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIC of the Office or upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in this apported in this apported in the communication THIS. This application is subject to	olication.  If not included will be mailed in due course. T	'HIS nitiati∨e
1. X This communication is responsive to the telephone Interview	v of February 17, 2004.		
2. X The allowed claim(s) is/are 122-134, 136-140, 145, now ren			
3. The drawings filed on 26 November 2001 are accepted by the	he Examiner.		•
4. ☐ Acknowledgment is made of a claim for foreign priority und a) ☐ All b) ☐ Some* c) ☐ None of the:			
1.   Certified copies of the priority documents have	been received.		
2.  Certified copies of the priority documents have	been received in Application No	·	
<ol> <li>Copies of the certified copies of the priority doc International Bureau (PCT Rule 17.2(a)).</li> </ol>	uments have been received in this	national stage application from	the
* Certified copies not received:			
5. Acknowledgment is made of a claim for domestic priority un reference was included in the first sentence of the specificat	ion or in an Application Data Sheet	onal application) since a specifi . 37 CFR 1.78.	ic
(a) The translation of the foreign language provisional ap		in a second	-111
6. Acknowledgment is made of a claim for domestic priority un in the first sentence of the specification or in an Application	der 35 U.S.C. §§ 120 and/or 121 si Data Sheet. 37 CFR 1.78.	nce a specific reference was in	ciuaea
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of the	this communication to file a reply co his application. THIS THREE-MOI	omplying with the requirements NTH PERIOD IS NOT EXTEND	noted ABLE.
7. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives	ted. Note the attached EXAMINER s reason(s) why the oath or declara	'S AMENDMENT or NOTICE O tion is deficient.	)F
8. CORRECTED DRAWINGS ( as "replacement sheets") must			
(a) ☐ including changes required by the Notice of Draftsperso	on's Patent Drawing Review ( PTO-	948) attached	
1) 🗌 hereto or 2) 🔲 to Paper No			
(b) ☐ including changes required by the proposed drawing co			
(c) $\square$ including changes required by the attached Examiner's	Amendment / Comment or in the C	Office action of Paper No.	_•
Identifying indicia such as the application number (see 37 CFR 1.1 each sheet. Replacement sheet(s) should be labeled as such in the	34(c)) should be written on the drawi e margin according to 37 CFR 1.121(	ngs in the front (not the back) of d).	
9. DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT FOR The	it of BIOLOGICAL MATERIAL I HE DEPOSIT OF BIOLOGICAL MA	must be submitted. Note the TERIAL.	
Attachment(s)			
1☐ Notice of References Cited (PTO-892)	5∐ Notice of Informal Pa	itent Application (PTO-152)	
2 Notice of Draftperson's Patent Drawing Review (PTO-948)	6⊠ Interview Summary (	PTO-413), Paper No	•
3 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No	/ Examiner 3 / interest		•
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ Examiner's Statemer 9∏ Other	nt of Reasons for Allowance	
		Phyllis G. Spivack Primary Examiner Art Unit: 1614	
		•	

Application/Control Number: 09/995,277

Art Unit: 1614

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Gary Connell on February 17, 2004.

Claims 108-113 and 116 are canceled.

The present Abstract is <u>deleted</u> and the Abstract below is <u>inserted</u> therefor.

## Abstract

Methods for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering pharmaceutical compositions comprising Fc modulating compounds are disclosed.

Any inquiry concerning this communication should be directed to Phyllis G.

Spivack at telephone number 703-308-4703.

Phyllis G. Spivack Primary Examiner

Art Unit 1614

PHYLLIS SPIVACK RIMARY EXAMINED

February 17, 2004